324 related articles for article (PubMed ID: 34398359)
21. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
22. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
Shoji H; Yamada Y; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Anticancer Res; 2015 Sep; 35(9):5055-61. PubMed ID: 26254407
[TBL] [Abstract][Full Text] [Related]
23. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.
Yasui H; Takeno A; Hara H; Imamura H; Akamatsu H; Fujitani K; Nakane M; Kondoh CN; Yukisawa S; Nasu J; Miyata Y; Makiyama A; Ishida H; Yoshida N; Matsumura E; Ishigami M; Sugihara M; Ochiai A; Doi T
Int J Colorectal Dis; 2022 Jun; 37(6):1393-1402. PubMed ID: 35585358
[TBL] [Abstract][Full Text] [Related]
24. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
Su X; Zhan P; Gavine PR; Morgan S; Womack C; Ni X; Shen D; Bang YJ; Im SA; Ho Kim W; Jung EJ; Grabsch HI; Kilgour E
Br J Cancer; 2014 Feb; 110(4):967-75. PubMed ID: 24457912
[TBL] [Abstract][Full Text] [Related]
25. Investigating FGFR2 gene as a blood-based epigenetic biomarker in gastric cancer.
Aleyasin SA; Moradi A; Abolhasani N; Abdollahi M
Mol Biol Rep; 2024 Feb; 51(1):253. PubMed ID: 38302798
[TBL] [Abstract][Full Text] [Related]
26. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
27. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
Katoh Y; Katoh M
Int J Mol Med; 2009 Mar; 23(3):307-11. PubMed ID: 19212647
[TBL] [Abstract][Full Text] [Related]
28.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
29. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract][Full Text] [Related]
30. FGFR2 gene amplification and clinicopathological features in gastric cancer.
Matsumoto K; Arao T; Hamaguchi T; Shimada Y; Kato K; Oda I; Taniguchi H; Koizumi F; Yanagihara K; Sasaki H; Nishio K; Yamada Y
Br J Cancer; 2012 Feb; 106(4):727-32. PubMed ID: 22240789
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.
Inokuchi M; Fujimori Y; Otsuki S; Sato Y; Nakagawa M; Kojima K
Gastroenterol Res Pract; 2015; 2015():796380. PubMed ID: 26000013
[TBL] [Abstract][Full Text] [Related]
32. FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort.
Schrumpf T; Behrens HM; Haag J; Krüger S; Röcken C
PLoS One; 2022; 17(2):e0264011. PubMed ID: 35167603
[TBL] [Abstract][Full Text] [Related]
33. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer.
Minashi K; Yamada T; Hosaka H; Amagai K; Shimizu Y; Kiyozaki H; Sato M; Soeda A; Endo S; Ishida H; Kamoshida T; Sakai Y; Shitara K
Jpn J Clin Oncol; 2021 Oct; 51(10):1523-1533. PubMed ID: 34258618
[TBL] [Abstract][Full Text] [Related]
34. Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments.
Kinoshita H; Yashiro M; Fukuoka T; Hasegawa T; Morisaki T; Kasashima H; Masuda G; Noda S; Hirakawa K
Carcinogenesis; 2015 Dec; 36(12):1511-20. PubMed ID: 26385890
[TBL] [Abstract][Full Text] [Related]
35. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor.
Kuroda K; Yashiro M; Miki Y; Sera T; Yamamoto Y; Sugimoto A; Nishimura S; Kushiyama S; Togano S; Okuno T; Ohira M
Cancer Sci; 2020 Dec; 111(12):4500-4509. PubMed ID: 32946655
[TBL] [Abstract][Full Text] [Related]
37. Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines.
Park S; Kim JH; Jang JH
Biochem Biophys Res Commun; 2007 Jun; 357(4):1011-5. PubMed ID: 17459342
[TBL] [Abstract][Full Text] [Related]
38. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Wainberg ZA; Kang YK; Lee KW; Qin S; Yamaguchi K; Kim IH; Saeed A; Oh SC; Li J; Turk HM; Teixeira A; Hitre E; Udrea AA; Cardellino GG; Sanchez RG; Zahlten-Kümeli A; Taylor K; Enzinger PC
Gastric Cancer; 2024 May; 27(3):558-570. PubMed ID: 38308771
[TBL] [Abstract][Full Text] [Related]
39. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
